These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 4511385)

  • 41. [L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].
    Sano I; Taniguchi K
    Munch Med Wochenschr; 1972 Oct; 114(40):1717-9. PubMed ID: 4538893
    [No Abstract]   [Full Text] [Related]  

  • 42. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 43. [Study of L-dopa treatment and its principal side effects in aged subjects].
    Antonini F; Baroni A; Bucalossi A; Roveyaz L
    Gerontol Clin (Basel); 1972; 14(5):297-309. PubMed ID: 4144357
    [No Abstract]   [Full Text] [Related]  

  • 44. L-DOPA in Parkinson's disease. Results of a co-operative study in the Montreal area.
    Mars H; Libman I; Schwartz AM; Gillo-Joffroy L; Barbeau A
    Can Psychiatr Assoc J; 1972 Apr; 17(2):123-31. PubMed ID: 5036506
    [No Abstract]   [Full Text] [Related]  

  • 45. [L-dopa treatment of persons with parkinsonism in a hospital for geriatric rehabilitation].
    Antonini F; Baroni A; Roveyaz L
    Sist Nerv; 1970; 22(2):74-81. PubMed ID: 5504560
    [No Abstract]   [Full Text] [Related]  

  • 46. [Case reports of some mental disorders in parkinsonian patients treated with L-dopa].
    Almici GM; Sbarbaro V
    Minerva Med; 1974 Feb; 65(8):398-401. PubMed ID: 4820722
    [No Abstract]   [Full Text] [Related]  

  • 47. A quantitative evaluation of the effects of L-dopa on Parkinson's disease.
    Velasco F; Velasco M
    Neuropharmacology; 1973 Feb; 12(2):89-99. PubMed ID: 4595553
    [No Abstract]   [Full Text] [Related]  

  • 48. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.
    Yahr MD; Duvoisin RC; Hoehn MM; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1968; 93():56-63. PubMed ID: 4885744
    [No Abstract]   [Full Text] [Related]  

  • 49. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J; Kase JC; Mena I; Palacios E
    Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
    [No Abstract]   [Full Text] [Related]  

  • 50. [Effects of L-dopa and stereotaxic surgery in Parkinsonism].
    Sugita K; Mutsuga N; Takaoka Y; Takeda A
    No To Shinkei; 1970 Sep; 22(9):1103-8. PubMed ID: 4918927
    [No Abstract]   [Full Text] [Related]  

  • 51. [New methods for measurement of the tremor and rigidity in patients with Parkinson's disease treated with L-Dopa].
    Paci A; Freddi A; Barba C
    Riv Neurol; 1973; 43(1):15-39. PubMed ID: 4698011
    [No Abstract]   [Full Text] [Related]  

  • 52. L-dopa in the treatment of Parkinsonism.
    Brezný I; Buranová D; Cernácek J; Trávniková M
    Act Nerv Super (Praha); 1972; 14(2):96. PubMed ID: 5040182
    [No Abstract]   [Full Text] [Related]  

  • 53. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 54. L-dopa in the treatment of parkinsonism.
    Haleem MA
    Gerontol Clin (Basel); 1972; 14(4):242-8. PubMed ID: 4634915
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G; Castaigne P; Lhermitte F; Beck H; Guillard A; Marteau R; Pepin B; Rondot P; Raphy B
    Rev Neurol (Paris); 1970 Feb; 122(2):89-102. PubMed ID: 4931719
    [No Abstract]   [Full Text] [Related]  

  • 56. Levodopa in treating Parkinsonism.
    O'Doherty DS
    Am Fam Physician; 1971 Nov; 4(5):95-9. PubMed ID: 5117507
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical effects of para-chlorophenylalanine in Parkinson's disease.
    Van Woert MH; Ambani LM; Levine RJ
    Dis Nerv Syst; 1972 Dec; 33(12):777-80. PubMed ID: 4272666
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 59. Efficacy of and possible differences in tolerance to L-dopa tablets with different rates of release of the active substance.
    Völler GW; Muschard F
    Acta Neurol Scand; 1974; 50(3):391-3. PubMed ID: 4525037
    [No Abstract]   [Full Text] [Related]  

  • 60. [Excitability of the spinal motor neurons in patients with Parkinsonism and athetosis treated with L-dopa].
    Messina C
    Riv Neurol; 1972; 42(3):225-31. PubMed ID: 5071006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.